For the first time, data from a study of hospitalized patients due to COVID-19 suggest that the disease may impair men’s testosterone levels.
Lead author Selahitin U Ayen, professor of urology, said that while it has already been reported that low testosterone levels may be the cause of worsening disease after a positive SARS-CoV-2 test, this is the first study to show That COVID-19 only reduces testosterone.
It is hoped that development may help explain why so many studies have found that male pregnancy is worse than those women with COVID-19, and therefore clinical using testosterone-based treatments To search for possible improvements in results.
“Testosterone is associated with the immune system of the respiratory organs, and low levels of testosterone may increase the risk of respiratory infections. Low testosterone is also associated with infection-related hospitalization and all-mortality in men in ICU patients Therefore, testosterone treatment may have benefits beyond improving outcomes for COVID-19 as well, ”explains Professor .ian.
“In our study, mean total testosterone decreased, as the severity of COVID-19 increased. Average testosterone levels were significantly lower in the ICU group than in the asymptomatic group. In addition, total testosterone levels were significantly lower. In ICU group compared to intermediate care unit group. Serum follicle stimulating hormone levels were significantly higher in ICU group than in heterogeneous group.
“We found, hypogonadism – a condition in which the body does not produce enough testosterone – 113 (51.1%) of male patients.
“Patients who died had lower total testosterone than live patients.
“However, 65.2% of the 46 male patients who were asymptomatic had loss of libido.”
The research team looked at a total of 438 patients. It consisted of 232 men, each confirmed SARS-CoV-2 in the laboratory. All data were collected prospectively. A detailed clinical history, complete physical examination, laboratory and radiological imaging studies were performed in each patient. All patients’ data were examined and reviewed by two physicians.
The cohort study was divided into three groups: asymptomatic patients (n: 46), symptomatic patients who were hospitalized in the Internal Medicine Unit (IMU) (n: 129), and patients who were intensive care units (ICU) ) (Was hospitalized) n: 46).
In patients who had a pre-Kovid-19 serum gonadal hormone test (n: 24), has the serum total testosterone level decreased significantly from the pre-Kovid-19 level of 458? ±? 198? Ng / dl to 315? 120 120? NG / dL at the time of COVID-19 in patients (P? =? 0.003).
Death was observed in 11 (4.97%) of male adult patients and 7 (3.55%) of female patients, suggesting no significance between the two sexes (p?>? 0.05).
Commenting on the results of the study, Professor: Yun stated: “It can be recommended that at the time of COVID-19 diagnosis, testosterone levels are also tested. In men with low hormones who have sex hormones COVID-19 tests positive for testosterone. Treatment may improve their prognosis. More research is needed on this. ”
Limitations of this study do not include that a control group of patients with conditions other than COVID-19, it was because of restrictions placed on the hospital that they were monitoring patients.
Future studies by the authors should look at the concentration levels of ACE2 (angiotensin-converting enzyme 2) – an enzyme that binds to the cell membranes of cells located in the intestines – in relation with total testosterone levels.